ReviewTargeted Therapeutics

Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges

See allHide authors and affiliations

Science Translational Medicine  28 Mar 2012:
Vol. 4, Issue 127, pp. 127rv2
DOI: 10.1126/scitranslmed.3001539

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Editor's Summary

The development of therapies for HER2-driven cancers illustrates the power of targeted treatments and the puzzle of drug resistance in the clinic.

View Full Text